^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ALA-101

    i
    Other names: ALA-101, CD19-directed CAR-iNKT, CAR19-iNKT
    Associations

    News

    Trials
    Company:
    Arovella Therap, Imperial College London
    Drug class:
    CD19 inhibitor, iNKT agonist
    Related drugs:
    Associations

    News

    Trials
    1year
    Engineering allogeneic off-the-shelf CD19-directed CAR-iNKT cells without additional genetic manipulations for the treatment of hematological malignancies (AACR 2023)
    These data demonstrate a unique, off the shelf CAR19-iNKT cell platform for targeting hematological malignancies that combines the specificity of CD19 targeting CAR with the innate features of iNKT cells. The data indicates that iNKT cells are a potent cell type for generating allogeneic off the shelf products for treating a broad spectrum of hematological malignancies and solid tumors by targeting different receptors on the respective tumors.
    IO biomarker
    |
    CD19 (CD19 Molecule)
    |
    CD19 expression
    |
    ALA-101